CC
NGNE icon

Commodore Capital’s Neurogene NGNE Stock Holding History

Commodore Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-427,866
Closed -$6.4M – 38
2025
Q2 		$6.4M Sell
427,866
-497,134
-54% -$7.8M 0.45% 31
2025
Q1 		$10.8M Buy
925,000
+125,000
+16% +$2.17M 0.8% 26
2024
Q4 		$18.3M Buy
800,000
+600,000
+300% +$22.3M 1.34% 20
2024
Q3 		$8.39M Hold
200,000
– – 0.52% 31
2024
Q2 		$7.28M Hold
200,000
– – 0.5% 30
2024
Q1 		$10.2M Buy
+200,000
New +$6.68M 0.68% 30

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital's NGNE Position: Q3 2025 in Review

Commodore Capital sold out of Neurogene (NGNE) in Q3 2025, closing a stake of 427,866 shares — an estimated $6.4M sold.

Commodore Capital first reported a position in NGNE in Q1 2024 and held it in 6 quarters. The position peaked at $18.3M in Q4 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q3 2025.

  • Commodore Capital reported no remaining Neurogene position as of Q3 2025 after selling out during the quarter.
  • Commodore Capital sold 427,866 Neurogene shares in Q3 2025, an estimated $6.4M.
  • Commodore Capital first reported a position in Neurogene in Q1 2024 and held it in 6 quarters.
  • Commodore Capital's Neurogene position peaked at $18.3M in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q3 2025.

Based on Commodore Capital's 13F filing for Q3 2025, filed 14 Nov 2025.